Our immune system implements an array of strategies to combat threatening infections. White blood cells called cytotoxic T ...
A key molecular mechanism drives the growth of liver cell cancer while simultaneously suppressing the body's immune response ...
Study suggests that persistently activated ATF6α is a tumor driver, a potential stratification marker for immunotherapy response, and a therapeutic target for HCC.
Magnetic nanoparticles engineered T cells inside living mice and guided them into solid tumors, achieving over 90% tumor ...
Human lung tissue analyses identify iNKT cell depletion as a mechanistic feature of advanced IPFFindings extend MiNK’s iNKT platform into chronic ...
Discover how Laverdia CA1 (verdinexor) treats canine lymphoma. Learn about the mechanism of action, handling precautions, and ...
Onchilles Pharma, a private biotech company pioneering next-generation cytotoxic therapeutics that harness the ELANE pathway, today announced the U.S. Food and Drug Administration (FDA) clearance of ...
Stanford University-led researchers report that tumor cells hijack mitochondria from immune cells, reducing anti-tumor immune function and activating cGAS-STING and type I interferon signaling that ...
Cancer cells have softer membranes than healthy cells. New nanoparticles exploit this physical difference to fuse selectively with tumors and deliver mRNA therapy with minimal off-target effects.
Memorial Sloan Kettering Cancer Center researchers have found RNA neoantigen vaccines that generate long-lived, functional CD8 + T cells in patients with pancreatic ductal adenocarcinoma (PDAC), ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results